Lovastatin: A Multifunctional Lipid-Lowering Agent with Emerging Therapeutic Potential in Wound Healing

Lovastatin, a potent member of the statin drug class, is primarily indicated for the management of hypercholesterolemia through the inhibition of 3-hydroxy-3- methylglutaryl-coenzyme A (HMG-CoA) reductase—an essential enzyme in the mevalonate pathway responsible for cholesterol biosynthesis. Traditionally prescribed for cardiovascular risk reduction, lovastatin has recently gained attention for its multifaceted pharmacological activities beyond lipid regulation. These include osteogenic properties promoting bone tissue regeneration, facilitation of fracture repair, and anti-inflammatory effects beneficial in dermatological conditions. However, its poor aqueous solubility and extensive first-pass metabolism have limited its systemic bioavailability and therapeutic efficacy in non-cardiovascular indications. Recent advancements in transdermal drug delivery systems, particularly microneedle- based patches, have shown promise in enhancing the dermal and systemic absorption of poorly water-soluble drugs like lovastatin. These systems offer targeted delivery, bypass first-pass metabolism, and improve patient compliance. Lovastatin’s pharmacokinetic profile reveals it is a lipophilic prodrug with high hepatic extraction and low oral bioavailability. It belongs to BCS Class II, characterized by low solubility and high permeability, and displays a high partition coefficient (Log P ~4.26). Its solubility is limited in water but adequate in organic solvents such as ethanol, DMSO, and DMF.